In addition, VIP down-regulated the gene expression of several Th17 and Th1 markers and pathogenic indicators including IL-22, IL-2, STAT3, IL-23R, and IL-21R in HD, but in eRA patients it only lowered IL-21, IL-2, and STAT3 expression. The gene discussed is IL22; the disease is Huntington disease.